Priority Review Voucher Accompanies FDA Approval of Impavido for Leishmaniasis | PharmaBoardroom
written on 25.03.2014
Tags:
,

Priority Review Voucher Accompanies FDA Approval of Impavido for Leishmaniasis

TAGS: ,

FDA approval of Impavido (miltefosine) to treat a tropical parasitic infection rare in the US has also earned Knight Therapeutics, Inc, a priority review voucher – the fourth-ever granted by the FDA. Knight is a spin-off of Paladin Labs Inc, the company that filed for Impavido approval. Knight formed in February when Endo Health Solutions […]

Latest Report